Konstantinos Xynos

CIK 1956241 · View on SEC EDGAR ↗

Insider

First SEC filing: Dec. 5, 2022 · Latest: Dec. 5, 2022

On this page

Insider at

Insider transactions

0 buys (P) 3 sells (S) Net: $-285,662 + 11 non-open-market transactions below last 12 months, based on the transactions shown below

Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted

11 other filings hidden
Date Ticker Code Shares Price Value Owned after Δ own A/D vs now
Aug. 10, 2026 REPL S 11,447 $12.97 $148,468 224,215 Direct -4.86% Disposed 12.8% (price as of 2026-08-21)
May 18, 2026 REPL S 14,023 $5.08 $71,237 235,662 Direct -5.62% Disposed 187.9% (price as of 2026-08-21)
Nov. 17, 2025 REPL S 7,248 $9.10 $65,957 139,685 Direct -4.93% Disposed 60.7% (price as of 2026-08-21)
May 20, 2025 REPL S 7,952 $8.06 $64,093 146,933 Direct -5.13% Disposed 81.5% (price as of 2026-08-21)
Nov. 18, 2024 REPL S 7,246 $10.78 $78,112 109,885 Direct -6.19% Disposed 35.7% (price as of 2026-08-21)
June 7, 2024 REPL S 10b5-1 15,881 $7.50 $119,108 117,131 Direct -11.94% Disposed 95.0% (price as of 2026-08-21)
May 16, 2024 REPL S 6,367 $6.47 $41,194 133,012 Direct -4.57% Disposed 126.0% (price as of 2026-08-21)
Nov. 16, 2023 REPL S 7,313 $10.92 $79,858 112,714 Direct -6.09% Disposed 33.9% (price as of 2026-08-21)
May 16, 2023 REPL S 771 $18.05 $13,917 120,027 Direct -0.64% Disposed -19.0% (price as of 2026-08-21)

P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding

Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.

Derivative holdings (Form 4 Table II)

Options, RSUs and convertible securities reported on Form 4 Table II.

Date Ticker Security Underlying Exercise price Expiration Shares A/D
April 1, 2026 REPL Employee Stock Option (right to buy) Common Stock (75,000) $7.61 April 1, 2036 75,000 Acquired
April 1, 2025 REPL Employee Stock Option (right to buy) Common Stock (67,500) $8.40 April 1, 2035 67,500 Acquired
April 1, 2024 REPL Employee Stock Option (right to buy) Common Stock (80,000) $7.73 April 1, 2034 80,000 Acquired
April 1, 2023 REPL Employee Stock Option (right to buy) Common Stock (75,000) $17.66 April 1, 2033 75,000 Acquired
Dec. 1, 2022 REPL Employee Stock Option (right to buy) Common Stock (26,250) $19.98 Dec. 1, 2032 26,250 Acquired

Exercise/conversion price is blank when not applicable (e.g. RSUs).

Initial ownership (Form 3) 5 holdings

Securities held when first becoming an insider, per SEC Form 3.

Date Ticker Security Shares Ownership
Dec. 5, 2022 REPL Common Stock 37,500 Direct
Dec. 5, 2022 REPL Common Stock 7,000 Direct
Dec. 5, 2022 REPL Common Stock 8,798 Direct
Dec. 5, 2022 REPL Employee Stock Option (right to buy)→ Common Stock (75,000) 75,000 Direct
Dec. 5, 2022 REPL Employee Stock Option (right to buy)→ Common Stock (10,500) 10,500 Direct

Compensation (DEF 14A)

Matched by name from proxy statements (DEF 14A) — verify against the filing.

REPL

Chief Medical Officer
Fiscal year Salary Bonus Stock awards Option awards Non-equity incentive Pension change Other Total
2025 $516,500 — $412,241 $430,688 $253,085 — $12,351 $1,624,865
2023 — — — — — — — —

Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.